A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Phase 1 Recruiting 140 enrolled Dizal Pharmaceuticals

RandomizedSequentialOpen-labelTreatment

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Evaluation	Drug	Modality	Dose	Route
Subject	DZD6008	Unknown	20 mg	Oral
Subject	DZD6008	Unknown	40 mg	Oral
Subject	DZD6008	Unknown	60 mg	Oral
Subject	DZD6008	Unknown	90 mg	Oral
Subject	DZD6008	Unknown	120 mg	Oral
Subject	DZD6008	Unknown	150 mg	Oral
Subject	Sunvozertinib	Small molecule	—	—